Scipio Bioscience raised EUR 6 million from an international syndicate led by M Ventures, the corporate venture capital arm of Merck. The initial shareholders Seventure Partners and High-Tech Gründerfonds participated in the capital increase, alongside additional investors Financière Arbevel and investiere. investiere contributed EUR 0.5 million in this round.

Scipio bioscience develops a new generation of single-cell sequencing solutions, to answer the growing needs of clinical and basic research labs. The patented technology is based on an innovative chemical approach conceived by its President and Co-Founder, Prof. Stuart Edelstein, a world-renowned biophysicist.

“Single-cell sample preparation is a major bottleneck in the sequencing workflow and represents a rapidly growing multi-billion market opportunity”, says Michael Lütolf, Investment Manager for investiere.

The company is headquartered in the iPEPS-ICM incubator of the Brain & Spine Institute in Paris.

The funding will fuel the final development of its single-cell RNA-sequencing kit, as well as marketing and business development efforts to prepare for commercial launch in 2022.

 

Written by

Investors

Verve Event Zurich Investors

Our sophisticated investors include visionary family offices, leading wealth managers, institutions, founders, and senior executives. These individuals and organizations are all committed to shaping the next generation of innovation.

Learn more

Privacy Preference Center